Biophotonic Nanoparticle-enabled Laser Blood Test for Early Detection of Pancreatic Cancer
Recruiting · NCT07659639 · Interventional (participants receive a specific treatment) · Lead sponsor: Fondazione Policlinico Universitario Campus Bio-Medico
View the official record on ClinicalTrials.gov →Interventions studied
Diagnostic procedures
What this trial is about
LASERBLOOD is based on a biophotonic technology that can be used to predict the development of Pancreatic Ductal Adenocarcinoma (PDAC) in particular categories of subjects at risk (e.g. persons with diabetes, obese people, patients with Intraductal Papillary Mucinous Neoplasm \[IPMN\] or other cystic diseases of the pancreas, etc.) and at the same time offer the possibility of verifying the real effectiveness of the treatments to which affected patients are subjected.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- for patients with PDAC and IPMN:\*\*
- No history of prior neoplastic diseases;
- Adequate renal and hepatic function;
- No hematologic disorders;
- Age ≥ 18 years;
- No active infections;
- Written informed consent.
- \*\*
Exclusion criteria
- \*\*
- Severe pre-existing medical conditions, such as serious illnesses or other medical conditions that could negatively affect study outcomes or pose a high risk to the patient's health;
- Ongoing therapies that could interfere with the study or alter the results.
Where it is running
1 location listed.
- Fondazione Policlinico Universitario Campus Bio-Medico - Rome, Italy, Italy